
    
      Preliminary data suggest intralesional rituximab is able to revert resistance to systemic
      rituximab in patients with CD20+ indolent lymphoma of the conjunctiva, and the addition of
      autologous serum seems to exhibit a synergistic effect on tumor regression. These two main
      aspects will be assessed in this trial.
    
  